



## King's Research Portal

DOI:

[10.1183/13993003.01610-2019](https://doi.org/10.1183/13993003.01610-2019)

*Document Version*

Peer reviewed version

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Spinou, A., & Chalmers, J. D. (2019). Respiratory physiotherapy in the bronchiectasis guidelines: is there a loud voice we are yet to hear? *The European respiratory journal*, 54(3). <https://doi.org/10.1183/13993003.01610-2019>

### **Citing this paper**

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### **General rights**

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### **Take down policy**

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

“This is an author-submitted, peer-reviewed version of a manuscript that has been accepted for publication in the European Respiratory Journal, prior to copy-editing, formatting and typesetting. This version of the manuscript may not be duplicated or reproduced without prior permission from the copyright owner, the European Respiratory Society. The publisher is not responsible or liable for any errors or omissions in this version of the manuscript or in any version derived from it by any other parties. The final, copy-edited, published article, which is the version of record, is available without a subscription 18 months after the date of issue publication.”

<https://doi.org/10.1183/13993003.01610-2019>

## **Editorial**

**Respiratory physiotherapy in the bronchiectasis guidelines. Is there a loud voice we are yet to hear?**

**Arietta Spinou<sup>1</sup>, James D. Chalmers<sup>2</sup>**

<sup>1</sup>Population Health Sciences, Life Sciences and Medicine, King’s College London, UK

<sup>2</sup>School of Medicine, University of Dundee, Dundee, UK

Corresponding author:

Dr Arietta Spinou

Email: [arietta.spinou@kcl.ac.uk](mailto:arietta.spinou@kcl.ac.uk)

Address: Lecturer in Cardiorespiratory Physiotherapy Practice and Research

Department of Population Health Sciences

School of Population Health and Environmental Sciences

2<sup>nd</sup> floor, Addison House, Guy’s Campus, King's College London

SE1 1UL, London, UK

Words: 1496

References: 40

Keywords: bronchiectasis, guidelines, clinical management, physiotherapy, airway clearance, pulmonary rehabilitation

Running title:

A call for action for great awareness and research into airway clearance techniques and pulmonary rehabilitation in bronchiectasis.

Bronchiectasis is a chronic respiratory disease of airway dilatation, where patients typically suffer from respiratory infections, fatigue, sputum, cough, dyspnoea, and poor quality of life.(1, 2) This condition receives increased interest over the last years, with important developments in establishing national and international patient registries(3-5), randomized controlled trials of new treatments(6-8) and disease-specific health status questionnaires, such as the Bronchiectasis Health Questionnaire and the Quality of Life – Bronchiectasis.(9, 10) A number of new treatment approaches have been proposed including long term antibiotic therapies and immune modulating drugs.(6, 7, 11, 12)

Nevertheless the area of bronchiectasis care that has received the least attention during this period is the aspect of management that most healthcare professionals caring for bronchiectasis agree is the most important, airway clearance and exercise.(13, 14) The evidence base for respiratory physiotherapy has not advanced at the same pace as other aspects of bronchiectasis care.(15)

To assist clinical decision making, bronchiectasis guidelines synthesise, evaluate the evidence and provide recommendations for clinical practice, and a number of clinical guidelines in bronchiectasis have been published since 2008 (Table 1). Although usually similar, guidelines could present some variability in their recommendations even for the same topic.(16-21) This is particularly the case for physiotherapy because of the limited evidence on which to base guideline recommendations. The purpose of this editorial is to discuss the current state of play worldwide with regard to airway clearance and pulmonary rehabilitation and suggest the need to prioritise research into these topics.

Current guidelines for the clinical management of bronchiectasis are available from national and international organisations: the European Respiratory Society (ERS 2017), British Thoracic Society (BTS 2019), Thoracic Society of Australia and New Zealand (TSANZ 2015), Spanish Society of Pulmonology and Thoracic Surgery (SEPAR 2018), Brazilian Thoracic Association (BTA 2019) and Saudi Thoracic Society (STS 2017).(16-21) All guidelines refer to adults with bronchiectasis, whilst TSANZ and STS also include children.(16-21) Most documents are similar in that they are developed by multidisciplinary teams, used pre-defined PICO (patient, intervention, comparison, outcome) questions and used systematic literature searches to identify relevant evidence. To ensure integrity of the clinical guidelines, all members of the development panels disclosed conflict of interests, and in the ERS panel the conflicted members did not vote on recommendations that were of potential conflict. Moreover, some guidelines reported on the involvement of public or patient representatives.(16, 18, 21)

Bronchiectasis guidelines discuss airway clearance techniques, muco-active treatment and pulmonary rehabilitation to a variable extent, along with their corresponding evidence. The guidelines universally recommend that patients with bronchiectasis should be taught, and should practice individualised airway clearance techniques and that this is best delivered by a respiratory physiotherapist (Table 1). The grade of relevant recommendations ranges from weak (ERS, BTS) to strong (SEPAR, TSANZ) and the quality of relevant evidence is rated as low (SEPAR, ERS, BTS, STS) to moderate (BTS, TSANZ) (Table 1).(16-21) Overall, airway clearance

techniques show a short-term improvement in quality of life, cough-related measures and sputum volume expectoration compared to sham intervention and inactive control groups.(22, 23) A recent randomized controlled trial in 44 patients also demonstrated a reduction in exacerbations with twice daily airway clearance.(24) ERS, SEPAR, BTA and STS provide some examples of commonly practiced airway clearance techniques. BTS guideline recommends offering the active cycle of breathing techniques or oscillating positive expiratory pressure to patients, as well as considering gravity assisted positioning when this is not contraindicated.(18) Still, little is known about the benefits of a specific technique over others and data mainly come from small and short-term studies, often with a cross-over design.(22) BTS additionally presents a list of clinical practice advice for airway clearance techniques and suggests management flowcharts during a clinically stable state and an acute exacerbation. This guideline discusses issues such as adherence, frequency of airway clearance techniques and review sessions, under “good practice points”, derived from expert opinion.(18)

Mucoactive treatments (expectorants, mucolytics, mucokinetics, and mucoregulators) are also discussed in all bronchiectasis guidelines.(16-21) These suggest offering long-term ( $\geq 3$  months) muco-active treatment in patients with difficulty expectorating sputum when standard airway clearance techniques are not adequate to control symptoms, rather than routinely. Most guidelines provide a strong recommendation against the use of recombinant human deoxyribonuclease (rhDNase) in bronchiectasis, as this is associated with higher exacerbation rate, more hospitalisations and a greater FEV<sub>1</sub> decline.(25, 26) BTS provides a weak recommendation to use humidification with sterile water or normal saline.(18) TSANZ advocates to consider mucoactive treatment such as hypertonic saline and mannitol in patients with frequent exacerbations rather than routinely, as longitudinal randomised controlled trials found that these provided little benefit over isotonic saline and placebo treatment, respectively.(27, 28) There is therefore little clarity over when to use mucoactive treatments and how to define “difficulty expectorating sputum with standard airway clearance techniques”.

Regarding pulmonary rehabilitation, small (<85 participants) and mainly short-term but well conducted randomised controlled trials show clinically significant improvements in exercise tolerance and quality of life; incremental shuttle walk distance mean change (95% confidence intervals, CI) 67 (52, 82) m and St George’s Respiratory Questionnaire mean change (95% CI) -4.65 (-6.7, -2.6) units, respectively.(26) Nevertheless a systematic review shows the evidence base for pulmonary rehabilitation consists of only 4 trials and 164 participants.(29) A recent study showed that pulmonary rehabilitation is equally effective in COPD and bronchiectasis.(30) There is a unanimously strong (ERS, SEPAR, TSANZ, BTS) recommendation for participating in pulmonary rehabilitation programmes when patients present impaired exercise capacity or report exercise limitation due to breathlessness. This recommendation was supported by moderate (TSANZ, SEPAR, STS) to high (ERS, BTS) quality of evidence.(16-21) When defined, exercise limitation due to breathlessness is indicated by a Modified Medical Research Council (MMRC) Dyspnoea scale score of  $\geq 1$ , which refers to the person that gets short of breath when hurrying on level ground or walking up a slight hill or feels

breathless even easier than that. ERS, BTS and SEPAR consider the addition of inspiratory muscle training to support the maintenance of the exercise benefit, although there are no evidence of an additive benefit to exercise tolerance or other clinical outcomes.(17, 18, 31) Availability of pulmonary rehabilitation in many countries in Europe is limited due to lack of resources and the lack of evidence.

Guidelines support airway clearance and the use of mucoactive treatment based on low to moderate level of evidence, which indicates that further research could change our confidence in the estimated effect. On the other hand, pulmonary rehabilitation is supported by moderate to high quality of evidence, providing greater confidence on the effect of this treatment. Patients seem to accept and value airway clearance techniques and pulmonary rehabilitation but long term compliance with them is unknown.(32) Moreover, airway clearance and pulmonary rehabilitation bronchiectasis recommendations largely rely on studies during a clinically stable stage. Thus, clinically, we are mainly called to extrapolate these results to disease exacerbations or assume that clinical outcomes will resemble those of other respiratory conditions; this could be misleading.

The evidence base for bronchiectasis therapy is evolving, but whereas several thousand patients have now been enrolled into trials of high cost therapies such as inhaled antibiotics or inhaled mucoactive drugs, trials that have been largely unsuccessful, there have been no large trials of airway clearance and pulmonary rehabilitation.(6, 8, 33) A search of Clinicaltrials.gov and other trial databases identified no trials with >100 participants of these two interventions. The UK CLEAR trial of hypertonic saline and carbocisteine is an encouraging development that will recruit 380 patients (ISRCTN89040295). The absence of standardised, quality assured airway clearance across centres participating in pharmacotherapy trials has been cited as one potential reason for their heterogeneous results.(34, 35)

Preliminary data show that access to airway clearance techniques and pulmonary rehabilitation is highly variable in patients with bronchiectasis across Europe.(35, 36) Bronchiectasis audits have also shown that implementation of the guidelines can be limited and even adherence to national standards on patient care is variable.(37-40) In the era of evidence-based medicine, evidence for what is considered usual care and a core part of bronchiectasis management is paramount for the implementation of the best available treatment. Once high-quality studies, evidence and strong clinical guidelines are available, our aim could focus on the local implementation. Still, it seems a long way to that, and the question remains “how could we address these outstanding uncertainties as a community”?

We issue a call to action, urging researchers, clinicians, funding bodies and the European Respiratory Society to prioritise airway clearance and pulmonary rehabilitation. Large randomized studies of these interventions are feasible, particularly with the availability of large registries and recently developed standardised endpoints.(41)

Clinical guidelines since 2008 have underlined the need for high quality evidence to support these therapies that bronchiectasis patients are recommended on a daily basis. Questions

that remain unresolved include the role of airway clearance in stable disease and exacerbation, the optimum method of clearance, duration and frequency for improving long term and clinically important outcomes in various disease severities. We need more data about the impact of airway clearance and pulmonary rehabilitation treatments in numerous areas, particularly exacerbations and hospitalisations; the role of physiotherapists in individualised action plans and home intravenous antibiotics; education in pulmonary rehabilitation; self-management; treatment compliance; and links between primary and secondary healthcare.

Airway clearance is largely individualised, and this remains a profound research challenge. It is acknowledged that large clinical trials including a comparator arm of no physiotherapy present ethical and logistical challenges as airway clearance is a standard part of care, and blinding is challenging. Innovative trial designs including cluster randomized approaches, active comparator studies or step-wedge implementation trials are alternatives which can overcome any barriers.

Great steps forward have been taken in changing bronchiectasis from an “orphan disease” but respiratory physiotherapy remains an orphan topic even in this “age of bronchiectasis”. This has to change, for the benefit of all our patients.

#### **Conflict of interest**

**James D. Chalmers** has received research grants from Glaxosmithkline, Boehringer Ingelheim, Astrazeneca, Pfizer, Grifols, Bayer AG, Polyphor and Insmmed; and received consultancy, congress travel or speaker fees from Glaxosmithkline, Bayer Healthcare, Aradigm Corporation, Grifols, Pfizer, Boehringer Ingelheim, Napp and Insmmed.

**Arietta Spinou:** none.

Table 1. Bronchiectasis clinical guidelines and their development methodology.

Guideline developers	Year	Databases of review	Last date of search	Level of evidence appraisal system
<b>ERS</b>	<b>2017</b>	PubMed -MEDLINE-, Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Library	Dec-16	GRADE
<b>BTS</b>	2010, <b>2019</b>	PubMed -MEDLINE-, EMBASE, Cochrane Library, Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessment (HTA), NHS Economic Evaluation Database (NHS EED)	Jun-16	SIGN
<b>SEPAR</b>	2008, <b>2018</b>	PubMed -MEDLINE-, EMBASE, Cochrane Library, Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessment (HTA)	Feb-17	GRADE
<b>TSANZ*</b>	2008, 2010, <b>2015</b>	PubMed, Cochrane Central Library	Oct-13	Revised GRADE
<b>BTA**</b>	<b>2019</b>	NR	NR	NR
<b>STS*</b>	<b>2017</b>	Not reported	Not reported	Costume-made appraising (A, B, C, D)

Current guidelines are in bold.

\*: indicates that the guidelines include recommendations for children

\*\*This guideline used a narrative literature review.

NR: none reported.

Costume-made appraising system: A indicating high quality of evidence from RCTs and meta-analysis to D panel consensus

**Abbreviations:**

ERS: European Respiratory Society, BTS: British Thoracic Society, SEPAR: Spanish Thoracic Society, TSANZ: Thoracic Society of Australia and New Zealand, BTA: Brazilian Thoracic Association, STS: Saudi Thoracic Society, GRADE: Grading of Recommendations Assessment, Development and Evaluation, SIGN: Scottish Intercollegiate Guidelines Network grading system.

Table 2. Overview of respiratory physiotherapy recommendations in current clinical guidelines.

Guidelines	Recommendation	Grade of recommendation	Quality of evidence
<b>Airway clearance techniques</b>			
<b>ERS 2017</b>	<ul style="list-style-type: none"> <li>teach ACT by respiratory physiotherapist</li> <li>perform ACT once or twice daily in chronic productive cough or difficulty to expectorate</li> </ul>	weak	low
<b>BTS 2019</b>	<ul style="list-style-type: none"> <li>teach ACT to perform</li> <li>offer ACBT or o-PEP</li> <li>consider gravity assisted positioning where not contraindicated to enhance effectiveness of ACT</li> </ul>	D D	3 to 1- 1-
<b>SEPAR 2018</b>	<ul style="list-style-type: none"> <li>ACTs are safe</li> <li>in stable bronchiectasis with productive cough (hypersecretion or frequent exacerbations)</li> </ul>	strong	low
<b>TSANZ 2015</b>	<ul style="list-style-type: none"> <li>perform ACT</li> <li>get respiratory physiotherapist's advice</li> <li>individualise ACT</li> </ul>	strong	moderate
<b>BTA 2019</b>	<ul style="list-style-type: none"> <li>teach and apply ACT to all patients with chronic production of secretions and/or (CT scan) signs of mucus plugging</li> </ul>	NR	NR
<b>STS 2017</b>	<ul style="list-style-type: none"> <li>lack of data about role of ACT in acute exacerbation, it may be used if no contraindications</li> <li>consider patient's preference and adherence to treatment</li> <li>teach patient or caregiver and encourage use of ACT and appropriate device</li> <li>ACT is safe and may improve sputum expectoration, lung function and quality of life in stable bronchiectasis</li> </ul>	NR NR	D C
<b>Mucoactive treatment</b>			
<b>ERS 2017</b>	<ul style="list-style-type: none"> <li>long-term mucoactive treatment in difficulty to expectorate sputum and poor quality of life, and where ACT cannot control symptoms</li> <li>rhDNase is contraindicated</li> </ul>	weak strong	low moderate
<b>BTS 2019</b>	<ul style="list-style-type: none"> <li>consider use of humidification with sterile water or normal saline</li> <li>do not routinely use rhDNSase</li> </ul>	D A	3 to 1+ 1+
<b>SEPAR 2018</b>	<ul style="list-style-type: none"> <li>insufficient evidence to recommend routine use of mucolytics</li> <li>hypertonic substances recommended in expectoration &gt;10 mL per day despite other treatment</li> </ul>	strong strong	low moderate
<b>TSANZ 2015</b>	<ul style="list-style-type: none"> <li>mucoactive agents are not routinely recommended</li> <li>consider trial in frequent exacerbations</li> </ul>	weak	moderate

<b>BTA 2019</b>	• rhDNase is contraindicated	strong	high
	• consider using hypertonic saline in persistent secretions despite other measures	NR	NR
	• supervise first administration of hypertonic saline to assess adverse events, which can be prevented or minimized by prior administration of short-acting bronchodilator	NR	NR
	• insufficient evidence to recommend routine use of mucolytics	NR	NR
<b>STS 2017</b>	• DNase is contraindicated		
	• nebulised saline or mannitol may increase ease of sputum expectoration and decrease its viscosity	NR	B
	• be aware of airway hyper-responsiveness, as it occurs in approximately 12% of patients	NR	D
	• rhDNase is not recommended as potentially harmful	NR	A
<b>Pulmonary rehabilitation</b>			
<b>ERS 2017</b>	• participate in PR • tailor to patient's symptoms, physical capability and disease characteristics	strong	high
<b>BTS 2019</b>	• offer PR to those functionally limited by shortness of breath (mMRC $\geq 1$ ) • consider the use of inspiratory muscle training in conjunction to PR to enhance maintenance of the training effect	B	1- to 1+
<b>SEPAR 2018</b>	• participate in PR • stable patients with mMRC dyspnoea scale $>1$	strong	moderate
<b>TSANZ 2015</b>	• participate in PR when exercise limitation	strong	moderate
<b>BTA 2019</b>	• refer to regular exercise and PR program, if available • in clinically stable patients with chronic hypercapnic respiratory failure, non-invasive mechanical ventilation by BiPAP should be used as an adjuvant to cardiopulmonary rehabilitation	NR	NR
<b>STS 2017</b>	• PR recommended as potential complementary option in moderate-to-severe disease	NR	C

**Explaining BTS grade of recommendation appraisal system:** A: a systematic review of RCTs or a body of evidence consisting principally of studies rated as 1+ directly applicable to the target population and demonstrating overall consistency of results, B: a body of evidence including studies rated as 2++ directly applicable to the target population and demonstrating overall consistency of results or extrapolated evidence from studies rated as 1++ or 1+, D: evidence of level 3 or expert opinion or extrapolated evidence from studies rated as 2+.

**Explaining BTS level of evidence appraisal system:** 1+: well conducted meta-analyses, systematic reviews of RCTs, or RCTs with low risk of bias, 1-: meta-analyses, systematic reviews of RCTs or RCTs with high risk of bias, 3: non analytic studies, for example, case reports, case series.

**Explaining STS system:** A: RCTs with rich body of data or meta-analysis from RCTs, B: RCTs with a limited body of data or meta-analysis from non-RCTs, C: non-randomised trials and observational studies, D: panel consensus.

**Abbreviations:**

ERS: European Respiratory Society, BTS: British Thoracic Society, SEPAR: Spanish Thoracic Society, TSANZ: Thoracic Society of Australia and New Zealand, BTA: Brazilian Thoracic Association, STS: Saudi Thoracic Society,

RCT: randomised control trial, ACT: airway clearance techniques, o-PEP: oscillatory positive expiratory pressure, BiPAP: bilevel positive airway pressure.

NR: none reported.

## References

1. Spinou A, Fragkos KC, Lee KK, Elston C, Siegert RJ, Loebinger MR, et al. The validity of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis. *Thorax*. 2016;71(8):683-94.
2. Guan WJ, Huang Y, Chen CL, Chen RC, Zhong NS. Macrolides, mucoactive drugs and adherence for the management of bronchiectasis. *Eur Respir J*. 2018;51(1):1701987; doi: 10.1183/13993003.01987-2017.
3. Chalmers JD, Aliberti S, Polverino E, Vendrell M, Crichton M, Loebinger M, et al. The EMBARC European Bronchiectasis Registry: protocol for an international observational study. *ERJ Open Res*. 2016;2(1):00081-2015; doi: 10.1183/23120541.00081-2015.
4. Araujo D, Shteinberg M, Aliberti S, Goeminne PC, Hill AT, Fardon TC, et al. The independent contribution of *Pseudomonas aeruginosa* infection to long-term clinical outcomes in bronchiectasis. *Eur Respir J*. 2018;51(2):1701953; doi: 10.1183/13993003.01953-2017.
5. Visser SK, Bye PTP, Fox GJ, Burr LD, Chang AB, Holmes-Liew C-L, et al. Australian adults with bronchiectasis: The first report from the Australian Bronchiectasis Registry. *Respiratory Medicine*. 2019;155:97-103.
6. De Soyza A, Aksamit T, Bandel TJ, Criollo M, Elborn JS, Operschall E, et al. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. *Eur Respir J*. 2018;51(1):1702052; doi: 10.1183/13993003.02052-2017.
7. Aksamit T, De Soyza A, Bandel TJ, Criollo M, Elborn JS, Operschall E, et al. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. *Eur Respir J*. 2018;51(1):1702053; doi: 10.1183/13993003.02053-2017.
8. Haworth CS, Bilton D, Chalmers JD, Davis AM, Froehlich J, Gonda I, et al. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with *Pseudomonas aeruginosa* (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials. *Lancet Respir Med*. 2019;7(3):213-26.
9. Spinou A, Siegert RJ, Guan WJ, Patel AS, Gosker HR, Lee KK, et al. The development and validation of the Bronchiectasis Health Questionnaire. *Eur Respir J*. 2017;49(5):1601532; DOI: 10.1183/13993003.01532-2016.
10. Quittner AL, Marciel KK, Salathe MA, O'Donnell AE, Gotfried MH, Ilowite JS, et al. A Preliminary Quality of Life Questionnaire-Bronchiectasis: A Patient-Reported Outcome Measure for Bronchiectasis. *Chest*. 2014;146(2):437-48.
11. De Soyza A, Pavord I, Elborn JS, Smith D, Wray H, Puu M, et al. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis. *Eur Respir J*. 2015;46(4):1021-32.
12. Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. *Jama*. 2013;309(12):1251-9.
13. Herrero-Cortina B, Vilaro J, Marti D, Torres A, San Miguel-Pagola M, Alcaraz V, et al. Short-term effects of three slow expiratory airway clearance techniques in patients with bronchiectasis: a randomised crossover trial. *Physiotherapy*. 2016;102(4):357-64.

14. Wong C, Sullivan C, Jayaram L. ELTGOL airway clearance in bronchiectasis: laying the bricks of evidence. *Eur Respir J*. 2018;51(1):1702232; doi: 10.1183/13993003.02232-2017.
15. Chalmers JD, Chotirmall SH. Bronchiectasis: new therapies and new perspectives. *Lancet Respir Med*. 2018;6(9):715-26.
16. Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. *Eur Respir J*. 2017;50(3):1700629; doi: 10.1183/13993003.00629-2017.
17. Martinez-Garcia MA, Maiz L, Oliveira C, Giron RM, de la Rosa D, Blanco M, et al. Spanish Guidelines on Treatment of Bronchiectasis in Adults. *Arch Bronconeumol*. 2018;54(2):88-98.
18. Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn SJ, Floto AR, et al. British Thoracic Society Guideline for bronchiectasis in adults. *Thorax*. 2019;74(Suppl 1):1-69.
19. Pereira MC, Athanazio RA, Dalcin PdTR, Figueiredo MRFd, Gomes M, Freitas CGd, et al. Brazilian consensus on non-cystic fibrosis bronchiectasis. *Jornal Brasileiro de Pneumologia*. 2019;45(4): e20190122.
20. Al-Jahdali H, Alshimemeri A, Mobeireek A, Albanna A, Al Shirawi N, Wali S, et al. The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis. *Annals of Thoracic Medicine*. 2017;12(3):135-61.
21. Chang AB, Bell SC, Torzillo PJ, King PT, Maguire GP, Byrnes CA, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. *Med J Aust*. 2015;202(3):130.
22. Lee AL, Burge AT, Holland AE. Airway clearance techniques for bronchiectasis. *Cochrane Database of Systematic Reviews*. 2015(11). doi: 10.1002/14651858.CD008351.pub3.
23. Lee AL, Burge AT, Holland AE. Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis. *Cochrane Database of Systematic Reviews*. 2017(9). doi: 10.1002/14651858.CD011699.pub2.
24. Munoz G, de Gracia J, Buxo M, Alvarez A, Vendrell M. Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial. *Eur Respir J*. 2018;51(1). doi: 10.1183/13993003.01926-2017.
25. O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. *Chest*. 1998;113(5):1329-34.
26. Wilkinson M, Sugumar K, Milan SJ, Hart A, Crockett A, Crossingham I. Mucolytics for bronchiectasis. *Cochrane Database Systematic Reviews*. 2014(5). doi: 10.1002/14651858.CD001289.pub2.
27. Bilton D, Tino G, Barker AF, Chambers DC, De Soyza A, Dupont LJ, et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. *Thorax*. 2014;69(12):1073-9.
28. Nicolson CH, Stirling RG, Borg BM, Button BM, Wilson JW, Holland AE. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. *Respir Med*. 2012;106(5):661-7.
29. Lee AL, Hill CJ, McDonald CF, Holland AE. Pulmonary Rehabilitation in Individuals With Non-Cystic Fibrosis Bronchiectasis: A Systematic Review. *Archives of physical medicine and rehabilitation*. 2017;98(4):774-82.e1.

30. Patel S, Cole AD, Nolan CM, Barker RE, Jones SE, Kon S, et al. Pulmonary rehabilitation in bronchiectasis: a propensity-matched study. *European Respiratory Journal*. 2019;53(1):1801264. doi: 10.1183/13993003.01264-2018.
31. Chalmers JD, Crichton M, Goeminne PC, Loebinger MR, Haworth C, Almagro M, et al. The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC): experiences from a successful ERS Clinical Research Collaboration. *Breathe (Sheff)*. 2017;13(3):180-92.
32. McCullough AR, Tunney MM, Quittner AL, Elborn JS, Bradley JM, Hughes CM. Treatment adherence and health outcomes in patients with bronchiectasis. *BMC Pulm Med*. 2014;14:107. doi: 10.1186/1471-2466-14-107.
33. Polverino E, Dimakou K, Hurst J, Martinez-Garcia MA, Miravittles M, Paggiaro P, et al. The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions. *Eur Respir J*. 2018;52(3). doi: 10.1183/13993003.00328-2018.
34. Chotirmall SH, Chalmers JD. RESPIRE: breathing new life into bronchiectasis. *Eur Respir J*. 2018;51(1):1702444; doi: 10.1183/13993003.02444-2017.
35. Flume PA, Chalmers JD, Olivier KN. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. *Lancet*. 2018;392(10150):880-90.
36. Walker P, Herrero B, Spinou A, Dimakou K, Blasi F, Ringshausen F, et al. Variability in access and referral to pulmonary rehabilitation in European bronchiectasis patients enrolled in the EMBARC registry. *European Respiratory Journal*. 2018;52(suppl 62):OA5201. doi: 10.1183/13993003.congress-2018.OA5201.
37. Herrero Cortina B, Aliberti S, Blasi F, Elborn S, Loebinger M, Menendez R, et al. Chest physiotherapy in European patients with bronchiectasis: Data from the EMBARC registry. *European Respiratory Journal*. 2017;50(suppl 61):PA4071. doi: 10.1183/13993003.congress-2017.PA4071.
38. Aliberti S, Hill AT, Mantero M, Battaglia S, Centanni S, Lo Cicero S, et al. Quality standards for the management of bronchiectasis in Italy: a national audit. *Eur Respir J*. 2016;48(1):244-8.
39. Hill AT, Routh C, Welham S. National BTS bronchiectasis audit 2012: is the quality standard being adhered to in adult secondary care? *Thorax*. 2014;69(3):292-4.
40. Hill AT, Welham S, Reid K, Bucknall CE. British Thoracic Society national bronchiectasis audit 2010 and 2011. *Thorax*. 2012;67(10):928-30.
41. Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. *European Respiratory Journal*. 2017;49(6):1700051. doi: 10.1183/13993003.00051-2017.